Indian investors remain hesitant about overseas investing due to taxation complexities and operational ambiguity. Expert Himanshu Kohli advises a strategic approach to global allocation, emphasizing rebalancing over timing. Opportunities lie in emerging markets and select US tech, energy, and defense sectors.
Oil prices surged to their highest levels since mid-2022 amid growing concerns over a prolonged U.S. blockade on Iranian exports and stalled nuclear negotiations. This disruption, potentially extending until a broader deal is reached, is tightening supply conditions and could lead to further price increases.
Vedanta anticipates a strong FY27 driven by record profits. The company plans to significantly reduce debt, invest in expansion, and continue rewarding shareholders. Leverage is projected to reach a new low. Vedanta is also proceeding with its demerger, with four new companies set to list soon. Some businesses are expected to be debt-free post-demerger.
Vedanta is set to undergo a significant restructuring. From May, the company will be divided into five separate entities. The main Vedanta entity will trade independently from Thursday, excluding the four newly demerged businesses. Shareholders will receive one share in each of the four new companies for every Vedanta share they hold.
Federal Reserve Chair Jerome Powell emphasized the critical need for the Fed to operate free from political influence to effectively serve the American people. He congratulated his likely successor, Kevin Warsh, on advancing through the Senate Banking Committee.
The Federal Reserve held interest rates steady for the third time, citing global risks like rising energy prices and supply disruptions. Policymakers are balancing inflation concerns with the potential impact of aggressive hikes on economic growth. This pause offers near-term stability for Indian markets, though elevated crude oil prices remain a significant worry.
Mining giant Vedanta is set to file for listing approval of its demerged companies next week. Shares of these new entities are anticipated to begin trading by mid-June. This strategic move will create five independent, sector-specific businesses. Each company will pursue its own growth path and attract investors.
Emcure Pharmaceuticals saw a significant block deal where BC Investments IV Limited sold 18 lakh shares for Rs 289 crore to Norges Bank. The pharma company, which manufactures APIs and formulations, has shown strong performance with a 67% return in the past 12 months and a 50% YoY growth in net profit.
Insurance companies reduced their stakes in top NSE large-cap stocks from December 2025 to March 2026. This decline, observed in companies like ICICI Bank and State Bank of India, suggests potential waning confidence or strategic reallocation of funds by insurers.
Warning! Information Posting in this website is only for educational purpose. We are not responsible for losses incurred in Trading based on this information.